Activating mutations in different domains of the ABCC8 gene-coded sulfonylurea receptor 1 (SUR1) cause neonatal diabetes. Here we show that a diabetogenic mutation in an unexplored helix preceding the ABC core of SUR1 dramatically increases open probability of (SUR1/Kir6.2) 4 channel (KATP) by reciprocally changing rates of its transitions to and from the long-lived, inhibitory ligandstabilized closed state. This kinetic mechanism attenuates ATP and sulfonylurea inhibition, but not Mg-nucleotide stimulation, of SUR1/Kir6.2. The results suggest a key role for L0 helix in KATP gating and together with previous findings from mutant KATP clarify why many patients with neonatal diabetes require high doses of sulfonylureas.
Introduction
ABCC8/KCNJ11-coded KATP [1] , stimulated by MgATP/ADP at the ABC ATPase and inhibited by ATP at the K + inward rectifier [2, 3] , control the metabolism-dependent excitability of pancreatic b-cells and certain neurons [4, 5] . Activating mutations in either KATP gene cause neonatal diabetes (ND), including severe ND with neurological abnormalities (see [6] [7] [8] and many additional reports reviewed in [9, 10] ). How ND mutations in different domains of SUR1 affect KATP open probability (P O ) and inhibition by sulfonylureas (SU) needs to be better understood.
The first functional analysis of ND mutations in the canonical TMD1-NBD1-TMD2-NBD2 core of SUR1 defined its Mgnucleotide-dependent hyperstimulation as the first, or A type, mechanism of pathogenic KATP overactivity [7] . Additional tests [11] uncovered that hyperstimulated KATP can show reduced responsiveness to sulfonylureas (SU), thus partly explaining why many ND patients need SU dozes exceeding those recommended by the FDA for treatment of adult-onset (type 2) diabetes (discussed in [9, 10] ).
A strikingly high percentage of ND mutations map to the L0 linker of the TMD0-L0 gatekeeper module ( Fig. 1 ) that couples the SUR1 core with the KATP pore and controls its nucleotideindependent P Omax [12, 13] . The first ND mutation found in the L0 linker, L213R, is in the middle of the hotspot region in the putative interface helix [14] and causes severe ND with neurological abnormalities [7] . We hypothesized that the mutation in the domain not required for nucleotide binding to SUR1 [12] hyperactivates KATP through a mechanism that is different from A type mechanism. Consistent with our hypothesis, the diabetogenic F132L in TMD0 of SUR1 increased KATP activity in the absence of nucleotides [15] .
The present study validates the hypothesis and establishes the kinetic mechanism of KATP hyperactivity and reduced SU responsiveness.
Materials and methods
Genetic and clinical testing showing that the mutation caused ND by compromising insulin release was described elsewhere [7] .
Homology models of the Sav1866-like human SUR1 core and the KirBac/KirChimera-like human K IR 6.2 pore were built as described previously [11, 13] . The mean helical hydrophobic moment was computed as described earlier [16] .
Mutagenesis, sequencing, cell culture and transfections were done as described earlier [7, 11] . Leu-213 is conserved in all SURs. L213R mutation was introduced into hamster SUR1 cDNA. SUR1 L213R or WT receptor was expressed with human K IR 6.2 and enhanced green fluorescent protein (a transfection marker) in COSm6 cells lacking any endogenous SUR or K IR .
Expression and SU binding/labeling of mature (complex-glycosylated, $170 kDa) and immature (core-glycosylated, $140 kDa) receptors were compared in SUR1 L213R /K IR 6.2-vs SUR1/K IR 6.2-expressing cells' membranes isolated and photolabeled with 125 I-azidoglibenclamide as described previously [17] . The incorporation of 125 I-azidoglibenclamide into different bands was estimated by densitometry of the autoradiographs and normalized to the membrane protein concentrations as described earlier [18] .
Patch-clamp recording and single-channel kinetics analysis were done as described previously [7, 11, [19] [20] [21] 
The Colquhoun-Hawkes test was used to evaluate the channel singularity. P Omax determined from single-channel and multi-channel currents were similar. N from macrocurrent noise analysis reflected the density of functional channels in the plasma membrane. All-points dwell time distributions were used to determine mean life times of all kinetic states and rates of burst-interburst gating transitions.
Ligand responses of KATP currents were obtained using an automated multi-channel rapid solution changer as described previously [7, 11, [19] [20] [21] [22] . To correct the ATP dose responses for partial rundown and/or refreshment of KATP currents the I value in the presence of each ATP concentration was normalized to the arithmetic mean of the I values before application of each [ATP] and after washout. Similar corrections were applied when estimating the steady-state activity in the presence of other ligands.
Statistical data analysis and curve fitting were done using OriginPro 8 (OriginLab Corporation, Northampton, MA) as described previously [11, 22] . Averaged data were expressed as mean ± S.E. for n P 5 with error bars equal to S.E. unless otherwise noted. Significance was evaluated using the unpaired t test. Differences with values of p < 0.05 were considered to be significant. Fig. 2 shows that L213R dramatically increases the Po in intact cells while not affecting i and slightly decreasing N. The latter effect is consistent with the small negative effect of L213R on the amount of mature receptor, which is in line with observations that a comparable amphipathic L0 helix of ABCC1 attaches to the membrane [23] and L225P in a less conserved portion of the cytoplasmic linker of SUR1 does not affect N [24] or surface expression of SUR1 in the same cell line [25] . The results show that L213R can induce pathogenic currents in intact cells by hyperactivating KATP and support the notion that possible negative effects of some ND mutations on N (see also [25] ) are overridden by their much stronger effect on P O .
Results and discussion
To establish the principal mechanism of pathogenic increase in on-cell P O it is essential to determine if and how the mutation affinity photolabeling of immature, core-glycosylated SUR1 L213R vs SUR1 with the second generation SU, and modestly reduced amount of mature, complex-glycosylated mutants trafficking with colabeled K IR 6.2. As was reported earlier, nanomolar glibenclamide or micromolar tolbutamide abolish labelling by displacing the photoreactive analogue of glibenclamide which does not label K IR 6.2 expressed without SUR1 [17, 18, 26] , the L0 loop apparently coordinates the photoreactive group-containing non-sulfonylurea moiety of the drug [22, 27] , and deleting the Nterminus of K IR 6.2 eliminates its colabeling without disrupting KATP assembly [18] required for trafficking of either SUR1 or glycosylation site-free K IR 6.2 to the plasma membrane [26, 28] . Therefore, normal affinity labeling of SUR1 L213R and K IR 6.2, while slightly reduced amount of mature SUR1 L213R , suggest that the mutation does not alter the SU binding site or the direct proximity of L0 to the K IR N-terminal helix, while slightly reducing KATP trafficking to the plasma membrane; n P 5 for each bar.
alters intrinsic gating kinetics (spontaneous bursting) and nucleotide inhibition vs Mg-nucleotide stimulation of the same population of channels before their significant rundown [11] . We obtained a significant number of single mutant and WT KATP records showing no significant rundown over minutes in the multivalent cation-free internal solution. Analysis of these records (Fig. 3) À1 [12] , by increasing T B and decreasing T IB , thereby limiting the availability of the longlived, inhibitory nucleotide-/SU-stabilized [4, 19, 29, 30] nonconductive C 2 state. The analysis of long, continuous, >3 kHz low-pass filtered single-channel records was essential for determining highly significant mean life times of all kinetic states in each KATP and demonstrating that reciprocal changes in rates of transitions to and from the long-lived closed state is the mechanism of P Omax saturation in the hyperactive KATP.
The mutation destabilizing the closed state with the Mgindependent micromoilar K D(ATP) [19, 21, 29] could attenuate ATP inhibition of macroscopic KATP currents without affecting their Mg-dependent nucleotide stimulation. To test this prediction we first compared the activities of the same macro-population of L213R channels in intact cells, in 1 mM MgATP, and in 1 mM ATP without Mg (Fig. 4A illustrates the protocol) vs similarly recorded activities of WT channels. We found (Fig. 4B ) similarly elevated activities of mutant KATP on cells and in the quasi-physiologic submembrane [MgATP] and similarly significant similar-fold decreases in the activities of both channels upon Mg removal. The results suggested that L213R does not alter the Mg-nucleotide stimulatory action but compromises the Mg-independent nucleotide inhibition of KATP. Indeed, the steady-state inhibitory ATP dose-response (Fig. 4C ) demonstrated that unlike A type mutations tested earlier under identical experimental conditions [7, 11] , L213R markedly ($20 times) increases IC 50(ATP) . Thus the mutation limiting the availability of C 2 state opens KATP in the presence of high intracellular [ATP], even without MgADP. This biophysical mechanism of KATP hyperactivity, called B type mechanism for short, explains why pancreatic b-cells in the L213R patient did not release insulin (remained hyperpolarized) despite his very high blood glucose [7] .
A dose of glibenclamide above the FDA recommended dose allowed to transfer the L213R patient from insulin injections to SU therapy [7] . We asked if the mutation attenuates KATP inhibition by SU despite essentially normal SU binding to SUR1 L213R / K IR 6.2 complexes (Fig. 2 inset legend) . Our first test (Fig. 5A ) indicated reduced inhibition of L213R channels by glibenclamide, but the slow washout of the second generation SU made it difficult to estimate its steady-state effect corrected for rundown (see Section 2 and similar test for WT KATP in [22] ). Therefore we used the rapidly unbinding SU tolbutamide to quantify the effect of L213R on KATP inhibition by [SU] saturating its specific, but not non-specific, sites [22, 31] . We compared the SU inhibition of L213R vs WT KATP activity under non-stimulatory conditions, as well as in the presence of the lowest possible submembrane [MgATP] and the highest possible [MgADP] in resting b-cells [32, 33] , as we did earlier for A type mutant KATP [7, 11] . We found that unlike A type mutations, L213R compromises SU inhibition under non-stimulatory conditions (Fig. 5B, left bars) . While saturation of specific SU binding sites with 200 lM tolbutamide reduces spontaneous activity of WT KATP by about 60% [22, 31] , the same SU treatment of L213R channels produces significantly smaller inhibition. Thus, L213R alters the nucleotide-independent component of SU action by uncoupling its high-affinity binding from the channel closure. Fortunately for ND patients, even lower [SU] significantly decreased the activity of B type channels in Mg-nucleotides (Fig. 5B, right bars) . This is consistent with findings that specific SU binding releases stimulatory nucleotides, thus abolishing KATP stimulation [22, 34] . This effect unmasks the inhibitory action of nucleotides less effectively in B type mutant channels because of their increased IC 50(ATP) . Thus, the mechanism of reduced SU responsiveness is fundamentally linked to the mechanism of K ATP hyperactivity.
The established kinetic mechanism of ND-SUR1/Kir6.2 hyperactivity and SU tolerance is consistent with early findings that SUR1/ DNKir6.2 channels with increased spontaneous activity show decreased sensitivity to ATP and SU [21, 22, [35] [36] [37] and inhibit insulin secretion in mice [38] . These and additional studies using chimeric SUR [20] , N-terminal Kir6.2 peptides [18] , and TMD0-L0 fragments [12] led us to the conclusion that TMD0-L0/M0-M1 interactions play key roles in KATP assembly and gating [13] . Consistent with the proposal, F132L in TMD0 and activating mutations in M0 alter intrinsic gating [15, 39, 40] . Strong effects of L213R in L0 helix on T B /T IB and KATP inhibition provide a new evidence in support of our working mechanistic model (Fig. 1) . Only subtle and insignificant functional effects of E208K [25] are not surprising. Unlike L213R, E208K can be carried asymptomatically [41, 42] and exchanges similarly hydrophilic side chains on the hydrophilic side of the submembrane amphipathic helix (Fig. 6) . Normal P Omax and ATP inhibition of SUR1 L225P /Kir6.2 channels [24, 25] are consistent with the prediction that a relatively short [14] interface L0 helix is a key element of the SUR1/Kir6.2 inhibitory machinery. So, it is tempting to speculate that L0 helix interacts with the equidistant [43] M0 ''slide'' [44] helix (Fig. 6 ) to lock the ligand-sensitive gate (Fig. 1) . The mechanistic interpretation is consistent with homologous structures [44] [45] [46] [47] [48] and single particle electron microscopy analysis of (SUR1-K IR 6.2) 4 [49] verifying that TMD0-L0 gatekeepers can fit between the K IR tetramer and four SUR1 cores and thus might transduce signals from the receptor core to the pore [12, 13] . A similar L0 helix was shown to interact with the conserved core in ABCC1 [23] , and we provided biochemical (labeling) evidence for the close proximity of ABCC8 L0 to the N-terminal domain of K IR 6.2 in inhibited KATP [18] . L213R does not alter the direct proximity of L0 to Kir6.2 (Fig. 2 inset) , but could disrupt optimized L0/M0 interactions by rotating the L0 helix along its axis (Fig. 6) as L213R changes the helical hydrophobic moment. The paradigm of evolutionary optimized L0/Kir6.2 interactions provides a basic explanation for the high concentration of spontaneous ND mutations in L0. Although our mechanistic model reconciles available data, it needs to be refined in additional studies.
Further functional analyses of new ND mutations in different parts of the TMD0-L0 gatekeeper module should shed more light on functional coupling between SUR1 and Kir6.2 and clarify if most of these mutations, causing $40% of ND-ABCC8 cases, overactivate KATP via B type mechanism. Previous studies showed that ND mutations in every major domain of the ABC core of SUR1 can increase KATP P O via A type mechanism (reviewed in [9, 10] ; see also [25] on V324M in TMD1). As we continue our search for the third, or C, type diabetogenic mutations altering the SUR1-induced decrease in the K D for inhibitory ATP [19] , it becomes evident that A and B mechanisms underlie the majority of ND-ABCC8 cases. This can explain why most ND-ABCC8 patients require body weightnormalized SU doses exceeding those prescribed to type 2 diabetes patients. Pharmacological testing of new ND-ABCC8/KCNJ11 recombinants will help evaluate this argument and identify SU resistant ND cases requiring alternative personalized therapeutic approaches. [7, 11] for details); n = 10 and R 2 > 0.995 for each curve fit. 
